Achillion Pharmaceuticals Inc., of New Haven, Conn., appointed Robert Van Nostrand to its board.
Affitech AS, of Oslo, Norway, appointed Thomas von Rüden to its supervisory board.
Aldagen Inc., of Durham, N.C., brought on Matthew Czajkowski as chief financial officer.
Array BioPharma Inc., of Boulder, Colo., appointed John Yates to the newly created position of chief medical officer.
Barrier Therapeutics Inc., of Princeton, N.J., appointed Braham Shroot to the newly created position of chief scientific officer.
Bayhill Therapeutics Inc., of Palo Alto, Calif., said Fred Kurland joined the company in the newly created position of chief financial officer.
Biogen Idec Inc., of Cambridge, Mass., named Lewis Klunk vice president, drug metabolism and pharmacokinetics.
BiPar Sciences Inc., of Brisbane, Calif., appointed John Schembri chief financial officer.
Calypte Biomedical Corp., of Lake Oswego, Ore., appointed Adel Karas to its board.
Cell Therapeutics Inc., of Seattle, chose Carl March president and CEO of its new subsidiary, Aequus BioPharma Inc. Stewart Chipman is executive vice president and chief scientific officer. David Cosman joined the company's board.
Ciphergen Biosystems Inc., of Fremont, Calif., appointed Steve Lundy senior vice president of sales and marketing.
Sofinnova Ventures, of San Francisco, added Bill Ringo to its life science team as executive-in-residence.
Tulip BioMed Inc., of San Diego, appointed Richard Burgoon Jr. as president and chief operating officer, and Kenneth Yonika, chief financial officer, secretary and treasurer.
U.S. Genomics Inc., of Woburn, Mass., added Salvatore Salamone to its board.
Velcura Therapeutics Inc., of Ann Arbor, Mich., named Bill Cadwallader executive vice president of corporate development.
ViRexx Medical Corp., of Edmonton, Alberta, elected Peter Smetek Jr., Michael Marcus, Yves Cohen, Douglas Gilpin and Jacques LaPointe to its board. Smetek also was appointed interim CEO.